Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
The restructuring leaves oncology and IDEC behind and reemphasizes the "Biogen" in Biogen Idec.